Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use

Lignende værker

• Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use
  af: Auriane Lesieur, et al.
  Udgivet: (2020-12-01)
• Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
  af: Yann Ferret, et al.
  Udgivet: (2018-05-01)
• Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria
  af: Raphael Itzykson, et al.
  Udgivet: (2011-06-01)
• Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort
  af: Augustin Boudry, et al.
  Udgivet: (2026-05-01)
• Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial
  af: Juliette Lambert, et al.
  Udgivet: (2019-01-01)